Breast Cancer

The Pharmacy Times® Breast Cancer resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
[[thumbnail_alt_text]]
The objective of the study was to examine whether positive treatment effects in cancer randomized clinical trials apply to specific demographic or insurance subgroups.
[[thumbnail_alt_text]]
There are few effective treatment options for patients with HER2-positive breast cancer who have received 2 or more previous therapies for advanced disease, according to the study authors.
[[thumbnail_alt_text]]
According to new research, biomarkers that signal whether a patient's cancer treatment may be harming their heart have been identified.
[[thumbnail_alt_text]]
Researchers have discovered a natural protective mechanism that leads to the programmed death of potentially diseased cancer cells.
 
[[thumbnail_alt_text]]
In a lecture at the virtual Community Oncology Conference 2020, Christine Roussel discussed some clinical considerations for the use of medical cannabis in patients with cancer.
[[thumbnail_alt_text]]
Research confirms earlier studies that found talazoparib improved patient-reported quality-of-life measures and had a tolerable safety profile.
 
[[thumbnail_alt_text]]
There are a variety of interventions that can be used to improve survival after a patient reports cancer toxicity following treatment.
[[thumbnail_alt_text]]
LGBTQ patients with cancer face specific barriers when seeking medical care, but pharmacists and other medical professionals can take specific steps to reduce care gaps.
[[thumbnail_alt_text]]
An expert panel at the Community Oncology Conference 2020 discussed how COVID-19 is changing the future of community oncology.
 
[[thumbnail_alt_text]]
New research has identified the binding site where drug compounds could activate a key braking mechanism against the runaway growth of many types of cancer.
[[thumbnail_alt_text]]
Sacituzumab govitecan-hziy is the first antibody-drug conjugates approved by the FDA specifically for relapsed or refractory metastatic triple-negative breast cancer (TNBC).
[[thumbnail_alt_text]]
Cancer cells avoid an immune system attack after radiation by taking control of a cell signaling pathway that helps dying cells avoid triggering an immune response.